Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.

Published

Journal Article

Medarex and Bristol-Myers Squibb are developing ipilimumab, an immunostimulatory human antibody against cytotoxic T-lymphocyte antigen-4, for the potential combination or monotherapy treatment of melanoma, prostate, breast, renal and other cancers, as well as HIV infection.

Full Text

Pubmed Central version

Duke Authors

Morse, Michael Aaron

Cited Authors

Morse, MA

Published Date

December 2005

Published In

Current Opinion in Molecular Therapeutics

Volume / Issue

7 / 6

Start / End Page

588 - 597

PubMed ID

16370382

Pubmed Central ID

16370382

Electronic International Standard Serial Number (EISSN)

2040-3445

International Standard Serial Number (ISSN)

1464-8431

Language

eng